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influenza (group C), and 8 healthy people who developed influenza
(group D.)
Methods: Case ascertainment through microbiology and electronic
medical records.
Results: Types of transplant: liver 3, heart 7, kidney 3, lung 8,
HSCT 8, kidney + pancreas 3, liver + kidney 1, liver + pancreas 1.
20 had influenza A, and 10 had influenza B (1 transplant recipi-
ent has both simultaneously.) Influenza occurred 1757 days (mean
[range 0-3850]) after transplant in group A, compared to 801 days
(range 20-3082) in group B. Influenza occurred 116 days (mean
[range 83-151] after vaccination in group A. There were no sta-
tistically significant differences in the incidence of fever, cough,
rhinorrhea, sore throat, malaise, shortness of breath, exposure to
contacts with similar symptoms, or presence of infiltrates on CXR
among groups A, B and D. Groups A and B were treated with os-
eltamivir significantly more frequently than Group D, [p=0.002].
Patients in group A were hospitalized more frequently than group
D [p=0.0002]. There were no statistically significant differences
in the incidence of pneumonia, ICU admission, mechanical ventila-
tion, or death among groups A, B and D. There were no statistically
significant differences between groups A, B and C in the incidence
of IgG < 600 mg/dL, immune function assay < 200 ng/mL, rejec-
tion (in SOT recipients) or GVHD (in HSCT recipients) in the preced-
ing 30 days. Patients in group A were significantly more likely to
have concomitant infections than group D [p=0.049], but not group
B.
Conclusions: Influenza vaccination did not alter clinical presenta-
tion of influenza in transplant recipients, or impact the incidence
of complications. Transplant recipients who developed influenza
despite influenza vaccination were not more immunosuppressed
than those who were vaccinated and did not develop influenza,
and were more likely to have concomitant infections than healthy
people.
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Oral Candidiasis in Solid Organ Transplant Recipients
Anna Dongari-Bagtzoglou1, E. Ioannidou1, P. Dwivedi1, D. Hull2,
J. Burleson1. 1University of Connecticut, School of Dental
Medicine, Connecticut, USA; 2Hartford Hospital, Connecticut, USA
Background: Oral Candida carriage and/or infection have been re-
ported to be associated with a greater risk for esophagitis and
pneumonitis in renal and liver transplant recipients; however a sys-
tematic analysis of the oral Candida titers and species has not been
previously conducted. The objectives of this study were to deter-
mine the prevalence of oropharyngeal candidiasis and to define the
oral carrier status, Candida titers and species in this population.
Methods: 144 kidney and heart transplant subjects were recruited
from Hartford Hospital of whom 90 met the following criteria
and were included in analyses: 1. clinically stable; 2. at least
one year post transplant; 3. no history of antifungal or antibi-
otic use within the last 4 months. Control subjects (n=72) were
age- and sex-matched, systemically healthy individuals. Subjects
received an oral clinical examination. Swabs from the oral mucosa
and a standardized amount of unstimulated saliva were plated on
Chromagar® plates, and CFU/ml were calculated. Initial speciation
was based on colony color and was confirmed by standard germi-
nation and biotyping (carbohydrate assimilation) assays.
Results: Significantly more transplant (7.7%) than control (0%)
subjects had oral infection with C. albicans (p=0.004). A signif-
icantly higher (p=0.039) frequency of asymptomatic colonization
was noted in transplant recipients (51.1%) compared to healthy
controls (29.2%). In addition, the transplant group had signifi-
cantly higher Candida titers than the control group (p=0.04). There
was a significant positive association between diabetes and his-
tory of anti-fungals (p=0.039) and a significant negative associa-
tion between Cyclosporine treatment and history of anti-fungals
(p=0.0003). There were no statistically significant relationships be-
tween the dose or type of immunosuppressants and oral Candida
titers or infection. 13.3% of transplant carriers and 4.2% of the
control subjects were colonized by more than one species, a differ-
ence that was statistically significant (p=0.045). The most frequent
combination in transplant patients was C. albicans and C. glabrata.
C.glabrata was isolated in 7.8% of transplant patients and none
of the controls, a difference that was also statistically significant
(p=0.016).
Conclusions: Increased oral Candida infection and carriage titers
were found in solid organ transplant subjects who are at least one
year post-transplant. Although the majority of these subjects are
colonized by C. albicans, C.glabrata appears to emerge as the sec-
ond most prevalent species.
Supported by NIH/NIDCR DE016466 and MO1RR06192.
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De Novo T-Lymphocyte Responses against
Baculovirus-derived Recombinant Influenzavirus
Hemagglutinin Generated by a Naive Umbilical Cord Blood
Model of Dendritic Cell Vaccination
Amar Safdar, William K. Decker, Sufang Li, Elizabeth J. Shpall. M.
D. Anderson Cancer Center, Houston, Texas, USA
Background: Cordblood-derived (CB) is an important source of
mostly unprimed stem cells. We sought to generate CB-derived
dendritic cells (DC) immunotherapy against influenzavirus.
Methods: Recombinant hemagglutinin (rHA) of H1N1 was expressed
by vector pPSC12 cloned baculovirus in SF9 cells. Generation of Im-
mature DCs. Umbilical cord blood units discarded from the MDACC
CB bank was used after IRB approval. DC loading and maturation:
in the presence of GM-CSF and IL-4, immature dendritic cells were
loaded with rHA protein. Immature DCs were suspended at a con-
centration of 4x107 cells/ml, mixed with rHA and incubated for
10 minutes on ice in an electroporation cuvette. T-cell priming
and re-Stimulation: matured loaded DCs were incubated at a ratio
of 1:10 with autologous non-adherent PBMCs (typically 50% CD3+),
plus IL-12. ELISpot Assay was performed using standard method.
ELISpots for putative HA peptide epitopes were performed similarly
using 1x 105 - 2x 105 lymphocytes incubated overnight in 3.75 mi-
crograms/ml peptide. T-cell specificity and functionality was then
demonstrated by 51Cr CTL lysis.
Results: rHA-specific lymphocytes demonstrate identifiable HLA-
restriction. HA-primed lymphocytes (HLA DRbeta1*1503) from a
different CB demonstrated a nine-fold increase in statistically large
spots when restimulated with the DR15-262 epitope (p<0.00002).
These data suggest that 1 in 1,900 of the HA-specific T-cells were
DR15-262 restricted in a highly-specific fashion. Total ELISpot num-
bers (p<0.0002) and total IFN-gamma release (p<0.00004) be-
tween lymphocytes restimulated with DR15-262 and the control
peptide were statistically distinct as well. Incubation of peptide
DR15-262 in conjunction with HA-primed/DR15- lymphocytes or
in conjunction with adenoviral hexon-primed (irrelevant) lympho-
cytes did not demonstrate significant numbers of IFN-gamma spots.
51Cr CTL assay demonstrates the generation of HA-specific cyto-
toxic T-cell effectors. Naïve cord blood T-cells were stimulated
three times with rHA-loaded dendritic cells; specific lysis of rHA-
loaded autologous DC was double that of unloaded control targets
at an E:T ratio of 5:1 (p=0.05).
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Conclusions: The results demonstrate that, despite the generally
naïve CB lymphocytes, influenza HA-specific responses can be gen-
erated ex vivo and could be potentially be used to enhance immune
reconstitution following allogeneic stem cell transplantation.
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Harvest and Preparation Techniques of the Blood Stem
Cells
Dorel Vlad1, Carmen Calugaroiu1, Virginia Mirea1,
Ramona Pasare1, Tatiana Puscariu2, Alexandra Dumitrescu2, Jeni
Laura Vlad3, Simona Dima4, Irinel Popescu4. 1Transfusions and
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3Microbiology Department; 4General Surgery and Liver
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Background: The purpose of the study was to obtain a quality
graft, which contained the minimum of 2.5x106/kg body stem cells
CD34 viable and functional.
Objectives: The principle was to base the separation of blood cells
using the difference between density gradients. We compared the
harvests on patients with: Hodgkin disease, multiple myloma, neu-
roblastoma, Ewing sarcoma, malignant non-Hodgkins lymphoma,
and acute leukemia.
Material and Methods: The study was undertaken between 2000
till November 2007 on 116 patients (97 patients and 19 donators)
in the Medullar Graft and Transfusions Centre, collaborating with
another department from Fundeni Clinical Institute. The total num-
bers of procedures was 188 (159 patients and 29 donators). The
harvest of peripheral blood stem cells were made by: medullar
aspiring puncture, citaferesys procedure, and/or umbilical vein
puncture, after expelling the afterbirth from uterus. We used de-
vices such as: Haemonetics MCS Plus and Cobe Spectra, and for
harvests made for liver and pancreatic transplantation the Clini-
macs Plus device system.
Results: In the case of harvests for patients with hematological
problems, we obtained 42 grafts CD34 <5x106/KgC and 74 grafts
CD34>5x106/KgC. For patients with diabetes, we obtained 2 grafts
CD34 >5x106/KgC. For patients with liver problems we obtained 4
grafts CD34 <5x106/KgC. All the grafts were bacteriological tested
by harvesting hem-cultures in BACTEC system, results were nega-
tive to the unfreeze blood stem cells graft and also when we veri-
fied the grafts after defrosting.
Conclusions: LVL versus SVL procedures comparison: a) LVL pro-
cedure allow the harvest of a large number of cells CD34+; b)
Viability of the cells CD34+ is not mutated; c) Number of neces-
sary aphaeresis to obtaining minimum 2.5x106 CD34/kgC is smaller
with LVL protocol, comparing with Haemonetics MCS Plus system.
The growing agent mobilization, for patients with liver and pan-
creatic problems, the harvest of CD34+ begins in the z+5-th day. If
you obtain an inadequate graft, you must undertake another blood
stem cells procedure harvest. In the wake of selection made with
Clinimacs Plus system we obtained 2 grafts, containing 0.01x109
leucocytes/bag and 0.001x106 CD34 cells/kgC, respective 1.02x109
leucocytes/bag and 2,18x106/kgC CD34 cells.
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Effect of Peri-transplant Linezolid on Time to Neutrophil
and Platelet Engraftment after Allogeneic Stem Cell
Transplantation (HSCT)
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Department of Medicine, Infectious Disease and Bone Marrow
Transplantation Services, Department of Biostatistics, Memorial
Sloan-Kettering Cancer Center, New York, USA
Background: Linezolid has been associated with low rates of re-
versible hematologic toxicities in clinical trials. Linezolid is the
preferred treatment for vancomycin resistant Enterococcus fae-
cium, a frequent cause of bacteremia post HSCT. We assessed the
impact of peri-HSCT Linezolid administration on the time to neu-
trophil and platelet engraftment.
Methods: Retrospective case control study. Cases were HSCT recip-
ients who received at least 7 consecutive days of linezolid starting
by day +7 post HSCT. Controls were matched to cases by age and
type of conditioning regimen and received at least 7 days of van-
comycin starting by day + post HSTC. The initial antibiotic regi-
men for fever and neutropenia was piperacillin/tazobactam plus
amikacin for adults, cefepime plus amikacin for children. Van-
comycin was initiated at the discretion of the treating physician.
Time to neutrophil engraftment (ANC_500) was calculated as the
number of days from stem cell infusion to absolute neutrophil
count (ANC)>500/mL on three consecutive measurements. Time to
platelet engraftment (PLT_20) was defined as the number of days
from stem cell infusion to date of maintaining platelet count (PLT)
>20,000/mL for 3 consecutive measurements without any platelet
transfusion for at least 7 days from the date of last PLT transfu-
sion. Statistical analysis was done using Fisher' s exact test and the
Wilcoxon rank sum test.
Results: Thirty-five cases were compared to 35 controls. Demo-
graphics and transplant characteristics were similar between cases
and controls. The median duration of treatment was 13 days for
linezolid (range 5-28) and 18 days for vancomycin (6-43). The cu-
mulative percentage of patients achieving ANC_500 and PLT_20
at each time point examined was similar for the two treatments
groups. The p-values from the competing risk analysis were not
significant (P=NS). The competing regression model confirmed this
conclusion after adjustment for factors know to affect engraft-
ment. WBC, ANC and PLT counts at 30 days after discontinuing
treatment were similar between the two groups.
Conclusions: Early linezolid administration did not have a negative
impact on time to neutrophil or platelet engraftment post HSCT.
Compared to controls cases had similar values of WBD, ANC and
PLT 30 days after discontinuing treatment. A larger study is needed
to validate our findings and assess the hematologic safety profile
of linezolid in the period of greatest marrow vulnerability.
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High Incidence of Human Herpesvirus 6 Reactivation in
Adult Recipients of Double Cord Blood Transplants
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Baltadakis1, Dimitri Karakasis1, Mary Anagnostopoulou2, Ioannis
Apostolidis1, Nicholas Harhalakis1, Olga Paniara2, Emmanuel
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Introduction: Human herpesvirus 6 (HHV-6) reactivation may have
significant consequences in cord blood transplant recipients (CBR).
This study evaluates the incidence of HHV-6 reactivation, its man-
ifestations and treatment in CBR at our center.
